Clinical Trial Update: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and dose-expansion Phase I/II clinical study of Dositinib Mesylate Tablets for locally advanced or metastatic non-small cell lung cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dositinib Mesylate Tablets (dositinib mesylate)

Snippet

Sponsor: Henan Genuine Biotech Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING